2AG

2AG is a major endocannabinoid produced from lipids in cellular membranes, mostly but not exclusively in response to cellular activity.

Psychosis and Schizophrenia

Schizophrenia is a chronic mental disorder that affects around 1% of the worldwide population. It causes psychotic behaviors, social and emotional disruptions and different cognitive impairments.

The causes of the disease are still not clear but studies show that both genetic and environmental factors have an effect on it.

Pain

pain is a very good target for therapeutic cannabinoids.

Obesity

Energy homeostasis (balance)  is one of the primary functions of the endocannabinoid system.

Diabetes

Diabetes has two major forms: Type 1 diabetes is an auto-immune disorder where insulin-producing β-cells in the pancreatic Islets of Langerhans are attacked by the body's immune system resulting in reduced insulin production. Type 2 diabetes results from increased tolerance of cells to insulin resulting in a reduced effect of insulin.

Alzheimer's disease

Alzheimer’s disease is a chronic neurodegenerative disease and the main cause of dementia. Main common symptoms of dementia are related with memory but other cognitive processes are affected during the development of the disease.

Addiction

Addiction is a complex physiological phenomenon that is intimately linked to the dopamine neurotransmitter system.

Virodhamine

Suspected endocannabinoid.

2OG

Suspected endocannabinoid. Does not bind classical endocannabinoid receptors (CB1/2) but targets GPR119.  

TREK-1

TREK-1 is a postassium channel that is constitutively leaky, thereby maintaining resting membrane potential. Mechanical membrane stretching and certain anaesthetics can open the channel, thus greatly reducing neuronal excitability.